Latest in Cardiovascular

Moderna and Chiesi establish collaboration for mRNA therapeutics

Moderna will receive $25m upfront and is eligible for more than $400m in development, regulatory, and commercial milestones

Find out more

Bio Protocol raises $6.9m to launch AI-powered decentralised science platform

The new platform enables researchers and patients to create "BioAgents" — autonomous AI co-scientists — to bring a faster, blockchain-verified path from lab to market
See more

Vitamin K2 technology wins award for NattoPharma spin-off

Kaydence Pharma has received a start-up award at the BIO International convention

Study: Vitamin K2 deficiency increases cardiovascular stress

Improving vitamin K2 status could benefit arterial stiffening and calcification, reducing cardiovascular complications, new study finds

US FDA approves cardiovascular medicine from Baxter

The premixed format of eptifibatide to treat acute coronary syndrome is the first of its kind available in a flexible container

Crown Bioscience expands cardiovascular and metabolic disease research capability

The company offers new non-GLP services and translational rodent models at its expanded site in Louisiana

Domainex expands partnership with ICL to reduce heart muscle damage during heart attacks

The aim is to discover a drug that inhibits the enzyme MAP4K4, which plays a key role in triggering cell death following a heart attack

Stem cell human heart tissue improves drug testing

Researchers at the Institute of Bioengineering and Nanotechnology and the Agency for Science, Technology and Research have engineered a 3D heart tissue from human stem cells, to test the safety and efficacy of new drugs on the heart

New research could help develop drugs to better address heart problems in diabetics

Researchers used a rat model to distinguish between the contributions of the two different beta-adrenoceptors

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced

Latest posts in Cardiovascular

Positive CHMP opinion for Cardioxane in Europe

Clinigen, global pharmaceutical and services company, will receive CHMP from the European Commission, following complications on paediatric use and regulation

Non-alcoholic steatohepatitis market to increase more than fortyfold by 2026

Currently, the NASH market has no approved therapies and is dependent on off-label agents offering sub-optimal safety and efficacy outcomes

Collaboration in bispecific-small-molecule drugs for metabolic disease

€250m agreement between Exscientia and Sanofi is for multiple-product development and licence option

Heart failure more fatal than common cancers

Primary care database study, separated by gender, is the first of its kind to compare survival of rates for these conditions

Nemera to work on nanotechnologies for cardiovascular diseases

The EU-funded project will foster the translation of nanomedical applications toward the cardiac field

Johnson and Johnson “most admired” pharma company

A survey conducted by Fortune determined that the company are most admired by peers out of all the pharma companies globally

Cardiac therapies catalysed by next-gen technology

Strong product pipeline will drive double-digit growth rates in the Western Europe and US markets, finds Frost & Sullivan’s Transformational Health team

Room for progress in dyslipidemia, say GlobalData

The data company has determined that unmet needs in dyslipidemia are set to endure, providing manufacturers with opportunities for development

Asia-Pacific antihypertensive therapeutics market to hit $27 billion by 2022, despite low innovation

The market for antihypertensive therapeutics across the five Asia-Pacific (APAC) countries of India, China, Australia, South Korea and Japan is set to grow from $19.1 billion in 2015 to $27 billion by 2022, at a compound annual growth rate of 5.1%, according to business intelligence provider GBI Research

Axiogenesis and Metrion Biosciences announce stem cell collaboration

Collaboration to develop human iPSC-derived cardiomyocytes and neurons for translational drug discovery

Beximco Pharma receives second product approval from the US FDA

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients

Sponsor content

Axol Bioscience launch Human iPSC-derived Atrial Cardiomyocytes

A consistent and reproducible model for drug development, toxicity testing and disease modelling applications

Vasoprotective and antihypertensive effects of Vascazen formulation presented at ESC Congress 2014

Vascazen has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles